Stephen ZR, Perazzolo S, Duan L, Eguchi M, et al. A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks. AIDS 2026 May 4. doi: 10.1097/QAD.0000000000004531.
PMID: 42084126